Market
Number of new NHS patients starting KIMMTRAK treatment by end of 2025?
2
Resolution / Starting Odds
Less than 200 • 25%
200 to 400 • 25%
400 to 600 • 25%
More than 600 • 25%
NHS official reports or press releases
Story
NHS Offers KIMMTRAK to HLA-A*02:01-Positive Adults with Previously Untreatable Uveal Melanoma
Dec 3, 2024, 07:10 AM
A significant advancement in cancer treatment has been announced in England, with hundreds of patients diagnosed with unresectable or metastatic uveal melanoma set to receive access to KIMMTRAK, a pioneering drug developed by Immunocore. The National Health Service (NHS) confirmed that this reimbursement agreement will allow HLA-A*02:01-positive adults to access the treatment, which is expected to extend their lives by several months. This breakthrough, described as a 'game changer,' was developed by a research team in Oxford and marks a major milestone for patients suffering from this rare and previously untreatable form of eye cancer.
View original story
Similar markets
150,001 to 220,000 • 25%
Less than 100,000 • 25%
100,000 to 150,000 • 25%
More than 220,000 • 25%
No • 50%
Yes • 50%
50,000 to 100,000 • 25%
Less than 50,000 • 25%
More than 150,000 • 25%
100,001 to 150,000 • 25%
50 to 100 hospitals • 25%
101 to 200 hospitals • 25%
More than 200 hospitals • 25%
Less than 50 hospitals • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
101-150 hospitals • 25%
0-50 hospitals • 25%
51-100 hospitals • 25%
More than 150 hospitals • 25%
Yes • 50%
No • 50%
100 to 200 • 25%
Less than 100 • 25%
More than 300 • 25%
200 to 300 • 25%
11-20 • 25%
0-10 • 25%
21-30 • 25%
31 or more • 25%
76% to 90% • 25%
50% to 75% • 25%
Less than 50% • 25%
More than 90% • 25%
